Isolated hepatic perfusion in the pig with TNF-α with and without melphalan

IHM Borel Rinkes*, MR de Vries1, AM Jonker2, TJG Swaak3, CE Hack4, PTGA Nooyen5, T Wiggers1 and AMM Eggermont1

1Department of Surgical Oncology, Rotterdam Cancer Institute/University Hospital Rotterdam; 2Laboratory of Pathology, Dordrecht; 3Department of Rheumatology, Rotterdam Cancer Institute/University Hospital Rotterdam; 4Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam; 5Department of Pathology, University Hospital Nijmegen, The Netherlands

Summary Isolated limb perfusion with tumour necrosis factor alpha (TNF-α) and melphalan is well tolerated and highly effective in irresectable sarcoma and melanoma. No data are available on isolated hepatic perfusion (IHP) with these drugs for irresectable hepatic malignancies. This study was undertaken to assess the feasibility of such an approach by analysing hepatic and systemic toxicity of IHP with TNF-α with and without melphalan in pigs. Ten healthy pigs underwent IHP. After vascular isolation of the liver, inflow catheters were placed in the hepatic artery and portal vein, and an outflow catheter was placed in the inferior vena cava (IVC). An extracorporeal veno-venous bypass was used to shunt blood from the lower body and intestines to the heart. The liver was perfused for 60 min with (1) 50 μg kg⁻¹ TNF-α (n = 5), (2) 50 μg kg⁻¹ TNF-α plus 1 mg kg⁻¹ melphalan (n = 3) or (3) no drugs (n = 2). The liver was washed with macrodex before restoring vascular continuity. All but one pig tolerated the procedure well. Stable perfusion was achieved in all animals with median perfusate TNF-α levels of 5.1 ± 0.78 × 10⁶ pg ml⁻¹ (± s.e.m). Systemic leakage of TNF-α from the perfusate was consistently < 0.02%. Following IHP, a transient elevation of systemic TNF-α levels was observed in groups 1 and 2 with a median peak level of 23 ± 3 × 10³ pg ml⁻¹ at 10 min after washout, which normalized within 6 h. No significant systemic toxicity was observed. Mild transient hepatotoxicity was seen in a similar extent in all animals, including controls. IHP with TNF-α with(out) melphalan in pigs is technically feasible, results in minimal systemic drug exposure and causes minor transient disturbances of liver biochemistry and histology.

Keywords: isolation; liver; perfusion; metastases; tumour necrosis factor

The liver is the commonest site of dissemination in patients with colorectal cancer (Bengmark, 1969; Wagner, 1984; Strangl, 1994). Five-year survival rates of up to 35% have been reported for patients amenable for partial hepatic resection (Hughes, 1986; Scheele, 1990; Van Ooyen, 1992; Sugihara, 1993; Que, 1994). Unfortunately, the vast majority of colorectal metastases confined to the liver are considered to be unresectable (Greenway, 1988; Cady, 1991; Genari, 1992). In addition, systemic chemotherapy has so far failed to provide satisfactory results in these cases (Kemeny, 1983, 1987). Therefore, it is mandatory to develop novel strategies to obtain tumour control in the liver.

The concept of locoregional administration of chemotherapy is aimed at achieving high local concentrations while minimizing systemic drug levels in an attempt to reduce dose-limiting side-effects. This might enhance anti-tumour efficacy as steep dose–response curves have been described for most chemotherapeutic agents (Frei, 1980; Canellas, 1987). Several techniques have been developed for regional therapy of hepatic malignancies, of which hepatic artery infusion (HAI) has become most widely used (Sullivan, 1964; Pentecost, 1993; De Takats, 1994). Although HAI has been shown to improve short-term tumour response rates over systemic chemotherapy, it only slightly affects survival, while significant dose-limiting toxicity has been encountered (Kemeny, 1987; Pentecost, 1993; De Takats, 1994; Chang, 1987). Alternatively, isolated hepatic perfusion (IHP), including total vascular isolation of the liver, has been reported to significantly increase intrahepatic drug concentrations when compared with HAI, while maintaining sufficiently low systemic drug levels (Aigner, 1982; Skibba, 1983; De Brauw, 1988; Marinelli, 1991; Radnell, 1990). However, large animal studies have revealed systemic leakage of the perfused anti-tumour agent owing to incomplete vascular isolation in up to 20% of animals (Sindelar, 1985; Van de Velde, 1986). Although incidental clinical reports on IHP have confirmed its potential use in humans (Aigner, 1988; Skibba, 1988; Hafstrom, 1994), it is clear that optimization of the IHP methodology is needed. In addition, a drug(s) that would provide optimal anti-tumour activity in the IHP setting is at present unknown.

High-dose tumour necrosis factor alpha (TNF-α) has been shown to be highly tumoricidal both in vitro and in vivo (Alexander, 1991; Jäättelä, 1991; Slihu, 1993). Many phase I and II studies have demonstrated that systemic administration of TNF-α in man results in considerable dose-limiting toxicity at dose levels at which no anti-tumour activity is observed (Asher, 1987; Blick, 1987; Feinberg, 1988). On the other hand, isolated limb perfusion with high-dose TNF-α in combination with the alkylating agent melphalan has recently been documented to be extremely effective in patients with irresectable soft-tissue...
surcomas and in patients with stage III melanoma (Eggermont, 1996a,b; Liénard, 1994). Although the exact mechanism of the anti-tumour action by TNF-α is unknown, endothelial injury of the tumour-associated vasculature has been suggested to play a pivotal role in inducing tumour necrosis (Watanabe, 1988; Renard, 1994; Cid, 1994). Thus, TNF-α may be effective against any histological tumour variant, provided that the tumour has a well-developed vascular bed.

It is not known whether intrahepatic administration of TNF-α via IHP is feasible with a satisfactory degree of safety. It is possible that TNF-α might induce significant hepatotoxicity as Kupffer cells are known to release various cytokines in response to TNF-α exposure (Shirahama, 1988; Busam, 1990). The present study in healthy pigs was performed to determine the effects of IHP with TNF-α, with and without melphalan, with emphasis on hepatic and systemic toxicity. For this purpose, a modification of previously reported IHP techniques was developed and tested.

MATERIALS AND METHODS

Isolated hepatic perfusion

Ten healthy pigs weighing 25–33 kg (median 30 kg) were used. All animals received humane care in compliance with the guidelines on animal welfare of the Erasmus University, Rotterdam. General anaesthesia was induced and maintained with pancuronium and fentanyl. Before surgery, all pigs received 0.1 ml kg⁻¹ Depomycine, consisting of 200 000 IU ml⁻¹ of procaine penicillin and 200 mg ml⁻¹ of dihydrostreptomycin. In all animals, an arterial line was introduced into the right carotid artery; a tunnelled double-lumen central venous catheter and Swan–Ganz catheter were placed in the right external and internal jugular veins respectively. In addition, the left external jugular vein was dissected in preparation for the veno-venous bypass shunt (see below). Via a midline abdominal incision, the liver was mobilized by transecting all ligaments, and the supra- and infraportal inferior vena cava (IVC) were dissected and encircled. The hepatoduodenal ligament was meticulously dissected preserving the common bile duct, coeliac trunk, portal vein (PV) and hepatic artery (HA). Branches of the PV and the HA, particularly those arterial branches running towards duodenum and stomach, were ligated as needed to obtain complete vascular isolation of the liver. The right common iliac vein was dissected free. After heparinization with 2 mg kg⁻¹ heparin, a veno-venous bypass circuit (VVB) was established using an inverted Y-shaped cannula to shunt mesenteric, renal and lower extremity blood around the liver back to the heart. For this purpose, a 20F cannula was introduced into the right common iliac vein, passed into the infrarenal IVC, and the free end was connected with one of the two lower limbs of the inverted Y. The left jugular vein was cannulated (20F) and connected to the upper limb of the inverted Y. To complete the VVB, the distal PV was clamped, cannulated (20F) and connected with the remaining lower limb. Directly before opening the VVB, a clamp was placed on the infrahepatic supraportal IVC, proximal from the cannula tip. The VVB flow was aided by a centrifugal pump (Medtronic, Biomedics, USA) in a manner identical to the technique currently used during liver transplantation procedures (Starzl, 1990). The liver perfusion circuit was established by introducing a 20F cannula into the hepatic side of the PV. A 24F venous outflow catheter was placed into the supraportal, infrahepatic IVC via a longitudinal phlebotomy (including the pericaval hepatic tissue) and passed into the retrohepatic IVC. These two catheters were connected to the extracorporeal circuit (see below) and, after clamping of the supraportal IVC and the hepatic artery (HA), portal liver perfusion was allowed immediately in an attempt to minimize anoxic liver damage (first anoxia time). Finally, the HA was cannulated with an 8F catheter, which was subsequently connected, thus completing the isolated liver perfusion circuit. The extracorporeal perfusion circuit consisted of a double head roller pump, VPCML membrane oxygenator with integrated heat exchanger and reservoir, and arterial blood filters, analogous to the extracorporeal circuit used during cardiopulmonary bypass procedures. The circuit was primed with 500 ml of colloid solution (Hesamcel) and 500 ml of porcine blood. In addition, sodium hydrocarbonate 8.4% was added to the priming infusion (15–20 ml). Portal and arterial flow rates and pressures, together with the oxygen saturation levels in the perfusate, were recorded as indicated by the heart–lung machine. The flow rates in the VVB shunt were also documented. In addition, the portal flow rates were measured before and immediately after IHP using an 8-mm 35B548 flow probe (Transonic Systems, Ithaca, NY, USA) connected to a Transonic T206X flowmeter (AB Medical, Roermond, The Netherlands). Once stable perfusion was established, as judged by the reservoir level, absence of systemic leakage from the IHP circuit was confirmed by injection of 1 cm³ of a 1:10 dilution of fluorescein into the arterial circuit, followed by illumination with a UV (Woods) lamp. The perfusate was heated to 40°C using a cooler/heater device and was kept at ≥ 39°C throughout the drug perfusion period. After 60 min of perfusion the liver was washed with Macrodec (≥ 1500 ml) until the fluid from the hepatic veins was clear. In order to restore physiological hepatic perfusion, the HA was decannulated and repaired with Prolene 7-0, whereas the HA and VCI clamps (second anoxia time) were placed. Next, the ICV and PV were decannulated and sutured (Prolene 5-0). The VVB was further dismantled by decannulating and ligating the left internal jugular vein and right common iliac vein respectively. Heparin was reversed by injection of protamine. Pigs were sacrificed 4–6 weeks after IHP.

Table 1 Technical data

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control (n = 2)</th>
<th>TNF (n = 5)</th>
<th>TNF/melphalan (n = 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anoxic period (min)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First</td>
<td>0 ± 0</td>
<td>1 ± 2</td>
<td>0 ± 0</td>
</tr>
<tr>
<td>Second</td>
<td>6 ± 1.4</td>
<td>13 ± 3</td>
<td>13 ± 3</td>
</tr>
<tr>
<td><strong>Flow rate VVB (ml min⁻¹)</strong></td>
<td>1125 ± 176</td>
<td>1053 ± 50</td>
<td>1117 ± 29</td>
</tr>
<tr>
<td><strong>Perfusion pressure (mmHg)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA</td>
<td>125 ± 35</td>
<td>110 ± 46</td>
<td>178 ± 54</td>
</tr>
<tr>
<td>PV</td>
<td>33 ± 4</td>
<td>38 ± 6</td>
<td>43 ± 6</td>
</tr>
<tr>
<td><strong>Perfusion flow rate (ml min⁻¹)</strong></td>
<td>225 ± 14</td>
<td>237 ± 121</td>
<td>178 ± 21</td>
</tr>
<tr>
<td>PV</td>
<td>470 ± 42</td>
<td>350 ± 71</td>
<td>407 ± 55</td>
</tr>
<tr>
<td>Perfusate oxygen saturation (%)</td>
<td>77 ± 2</td>
<td>73 ± 5</td>
<td>72 ± 1</td>
</tr>
</tbody>
</table>

*Technical perfusion data as indicated by pump and heart–lung machine. Data are presented as means ± s.e.m. First anoxic period is defined as time between clamping and portal perfusion; second anoxic period as time between initiation of wash out and arterial recirculation.
Isolated hepatic perfusion with TNF-α

![Graphs showing liver biochemistry parameters over time](image)

**Figure 1.** Course of liver biochemistry parameters as a function of time (days) following hyperthermic isolated hepatic perfusion (IHP) in pigs on day 0. Error bars have been omitted for reasons of clarity. Standard deviations never exceeded 10% of the mean values depicted. -■-, Control; +, TNF; ×, TNF + melphalan

**Drugs**
Recombinant human tumour necrosis factor alpha (rhTNF-α) (0.2 mg per ampoule) was a kind gift from Boehringer Ingelheim, Germany. The cytostatic drug melphalan (Alkeran) was obtained as a sterile powder (100 mg) that was dissolved aseptically using solvent and diluent by Burroughs Wellcome (London, UK).

**Treatment schedule**
In five pigs, a 60-min hyperthermic IHP was performed with rhTNF-α (50 μg kg⁻¹) alone, while three pigs were treated by IHP with rhTNF-α (50 μg kg⁻¹) plus melphalan (1 mg kg⁻¹). TNF was administered as a bolus in the arterial line of the perfusion circuit; melphalan was given directly following the rhTNF bolus. In two control pigs, no drugs were added (sham group).

**Sampling schedule**
Pertussis was sampled at t = 0 (i.e., upon drug administration), 15, 30, 45 and 60 min. Systemic blood samples were collected the day before IHP, during IHP at t = 0, 15, 30, 45 and 60 min and after perfusion at t = 1, 10, 30, 60, 120 and 480 min, days 1, 3, and 7 and weekly thereafter. Blood samples were centrifuged at 5000 r.p.m. for 5 min. Supernatants were stored at -70°C until analysis. Biliary samples (approximately 5–10 ml) were taken by direct puncture of the gall bladder before IHP, immediately after IHP and upon closure of the abdomen.

**TNF-α assay**
TNF-α was measured by a sandwich-type ELISA using two monoclonal antibodies (Department of Immune Reagents, Central
Laboratory of Blood Transfusion, Amsterdam, Netherlands) raised against rhTNF-α (courtesy of Dr A Creasey, Chiron, Emeryville, CA, USA). One MAb (MAb CLB-TNFα-7) was used for coating at a concentration of 2 μg ml⁻¹; the second MAb (MAb CLB-TNFα-5) was biotinylated and used in combination with streptavidin poly-horseradish peroxidase conjugate to detect bound TNF-α. Stimulated human mononuclear cell supernatant was used as a standard for comparison with purified rhTNF-α. Results were expressed as pg ml⁻¹ by reference to this standard.

Histology

Multiple liver biopsies were taken before and directly after IHP and upon sacrifice at 4–6 weeks post-operatively. The tissue samples were fixed in formaldehyde and embedded in paraffin. Five-micrometre sections were stained with haematoxylin and eosin (HE). In addition, samples were taken from all animals in preparation for electronmicroscopy (EM).

Statistics

Comparisons within and between groups were made by analysis of variance for repeated measurements (ANOVA) or by the t-test where appropriate. Correlations between maximum or minimum levels of parameters were calculated as Spearmann’s rank correlations. The significance level was taken as a probability (two-sided) of < 0.05.

RESULTS

The duration of the operation ranged from 4 to 7 h (median 6 h). In all animals, a stable perfusion was achieved with no apparent leakage as demonstrated by the fluorescein dye injection. Further technical details are summarized in Table 1. As indicated by the oxygen saturation levels in the perfusate, adequate tissue perfusion was attained in all cases. In addition, the measured flow rates in the PV did not differ significantly before and after IHP in all groups. Median blood loss was 500 ml (range 300–1500 ml), including blood lost in the perfusion circuit. All pigs survived the operation. One animal in the TNF-alone group died on the first post-operative day. At necropsy, clear, serosanguinous fluid was observed in the abdomen without evidence of portal hypertension/thrombosis or surgical haemorrhage. One pig in the TNF/melphalan group underwent relaparotomy for hernia cicatrix. At the time of necropsy, all remaining animals were in good general condition, with weights ranging from 30 to 40 kg. In fact, 4 weeks after IHP; one pig in the TNF-alone group developed pneumonia with elevated leucocyte counts 4 weeks after perfusion. One pig in the TNF/melphalan group underwent relaparotomy for hernia cicatrix. At the time of necropsy, all remaining animals were in good general condition, with weights ranging from 30 to 40 kg. In fact, 4 weeks after IHP, all surviving animals had gained weight. Weight gains did not differ significantly between groups. Macroscopic post-mortem examination did not reveal any intra-abdominal or intrathoracic abnormalities.

In all animals, IHP resulted in significant elevations of ASAT, ALAT, LDH and alkaline phosphatase levels, with peak values occurring on day 1 post-operatively (Figure 1). Transaminase levels returned to normal within the first 7–10 post-operative days, while alkaline phosphatase and LDH remained slightly elevated throughout the observation period. Total bilirubin values remained within the normal range (Figure 1), as did the serum values of urea, γ-GT and creatinin (data not shown). There were no significant differences in peak values or kinetics between the three groups. In all groups, serum albumin levels decreased to a nadir of approximately 22 g l⁻¹ on the first post-operative day and returned to normal values within the next 7–14 days, (Figure 1).

Haemoglobin and haematocrit remained normal throughout the follow-up period (data not shown). In contrast, platelet counts decreased slightly, but not significantly, during the first post-operative day and normalized within 3–7 days.

TNF-α levels in the perfusate of the pigs in the TNF-alone group increased to a median of 5.0 × 10³ pg ml⁻¹ (range 4.9–6.3 × 10³); compared with 5.2 × 10³ pg ml⁻¹ (5.1–6.6 pg ml⁻¹) in the TNF/melphalan group. These perfusate TNF-α levels remained virtually stable throughout the 1-h perfusion period. Per fusate TNF-α levels in the control group remained normal (i.e. < 5 pg ml⁻¹) during IHP (Figure 2). At t = 0 (i.e. at the beginning of the perfusion), all animals displayed normal systemic TNF-α levels. During IHP, systemic TNF-α levels in the control group increased to a median of 5.0 × 10³ pg ml⁻¹ (range 4.9–6.3 × 10³); compared with 5.2 × 10³ pg ml⁻¹ (5.1–6.6 pg ml⁻¹) in the TNF/melphalan group. These perfusate TNF-α levels remained virtually stable throughout the 1-h perfusion period. Per fusate TNF-α levels in the control group remained normal (i.e. < 5 pg ml⁻¹) during IHP (Figure 2). At t = 0 (i.e. at the beginning of the perfusion), all animals displayed normal systemic TNF-α levels. During IHP, systemic TNF-α levels in the control group increased to a median of 5.0 × 10³ pg ml⁻¹ (range 4.9–6.3 × 10³); compared with 5.2 × 10³ pg ml⁻¹ (5.1–6.6 pg ml⁻¹) in the TNF/melphalan group. These figures indicate that, in both experimental groups, cumulative systemic leakage of TNF-α from the perfusate was less than 0.02% during the 60-min perfusion. However, following washout and decannulation at the end of the perfusion, systemic TNF-α levels increased significantly in the TNF-alone group.
and the TNF/melphalan group, with median peak levels of $3.2 \times 10^3$ pg ml$^{-1}$ and $17 \times 10^3$ pg ml$^{-1}$ respectively (Figure 2). These peak levels occurred between 1 and 30 min (median 10 min) after washout and returned to normal within 480 min after IHP. Again, there were no significant differences between the two experimental groups. Systemic post-perfusion TNF-α levels in the control animals rose slightly, but not significantly, to a maximum value of 26 pg ml$^{-1}$ at $t = 60$ min after washout. None of the biliary samples evaluated contained detectable levels of TNF-α.

Compared with pre-perfusion histology, microscopic examination of HE-stained sections taken directly after perfusion showed mild sinusoidal dilatation as well as septal oedema with sporadic intrasplenic polymorphonuclear cell (PMN) infiltration. These findings were documented in all animals, including the controls. There was no apparent hepatocellular damage or parenchymal necrosis. At 4–6 weeks after IHP, all microscopic sections revealed normal pig liver histology (on both HE and EM), with the exception of sporadic PMN infiltrates in the liver parenchyma. The septal oedema and sporadic septal infiltration had disappeared in all specimens investigated. Again, these findings were similar in all three groups.

**DISCUSSION**

The data presented here demonstrate that, in the pig model used, hyperthermic isolated perfusion of the liver via both the HA and the PV is technically feasible and appears to be a safe procedure. Nevertheless, the current IHP technique still involves a large operation, as illustrated by the median duration of 6 h and the one post-operative death. Additional modifications, including the use of balloon catheters, are therefore being studied at present. Temporary exposure of normal porcine liver parenchyma to high-dose rhTNF-α, with and without melphalan, in combination with hyperthermia is well tolerated and results in mild, transient hepatotoxicity. This was illustrated by early elevation of liver enzyme levels, followed by a spontaneous return to normal levels. On histological examination, immediate post-perfusion changes included sinusoidal dilatation and mild septal oedema, without any signs of hepatocellular injury. Sections taken 4–6 weeks after IHP revealed sporadic, perportal infiltrates in otherwise normal hepatic parenchyma. Most biochemical and histological alterations following IHP were similar in both control and experimental animals. This suggests that the mild hepatotoxic phenomena observed were primarily caused by the IHP procedure itself and that the addition of the drugs used, in particular rhTNF-α, does not lead to additional hepatotoxicity. These findings are in agreement with those reported on IHP with hyperthermia and/or standard chemotherapeutics (Skibba, 1983, 1988; Sindelar, 1985; Van de Velde, 1986; Aigner, 1988; Hafstrom 1994).

Complete vascular isolation of the liver during IHP is essential to avoid systemic exposure to high doses of antitumoral agents. Previous studies on IHP in large animals, using somewhat different methodologies, have mentioned technical difficulties resulting in incomplete vascular isolation and systemic leakage of drugs. Van de Velde et al (1986) reported leakage in 3 out of 15 pigs treated with IHP, whereas Sindelar et al (1985) encountered incomplete vascular isolation in 2 out of 10 pigs, resulting in severe systemic drug-associated toxicity and death. In these studies, either a passive external or an internal venous shunt was employed to drain distal portal and lower body blood. In view of their findings, we modified the IHP technique in an attempt to minimize leakage. This modification involved the introduction of a separate, second active circuit which consisted of a pump-aided, extracorporeal veno-venous bypass shunt (VVVB) connecting cannulas in the distal PV and infrahepatic IVC with the external jugular vein. Besides simplifying the hepatic perfusion circuit in this manner (as opposed to internal venous shunts), the VVB has the additional advantage of more efficiently shunting blood from the lower body, kidneys and intestines to the heart. As a result, the cardiac venous return increases, thereby augmenting haemodynamic stability throughout the procedure. In fact, we did not observe any haemodynamic instability during our experiments in pigs, generally considered to be haemodynamically sensitive. Moreover, we have been able to detect that there was no significant leakage from the liver perfusion circuit to the systemic circulation. This was achieved using either of two qualitative methods, i.e. observing fluorescent dye distribution or monitoring perfusate reservoir levels. This was confirmed in a quantitative manner by analysing, during the vascular isolation period, systemic levels of TNF-α, which remained approximately four orders of magnitude lower than perfusate levels. In addition, all pigs survived the procedure and no animal demonstrated any of the known systemic side-effects of rhTNF-α in pigs during and after IHP (Leighton, 1991; Tuog, 1992).

However, following IHP and washout, an additional rise in systemic TNF-α levels was seen upon restoration of vascular continuity. Although well below toxic concentrations of rhTNF-α in the pig, this phenomenon still has to be accounted for. It is possible that the washout procedure was not sufficiently effective in removing all remaining TNF-α from the perfusate. This may be particularly true in the non-tumour-bearing pig liver, in which virtually no TNF-uptake was observed during IHP, as judged by perfusate TNF-α levels (Figure 2).

There is no consensus on the route of infusion (HA vs PV vs both). Normal hepatic parenchyma receives most of its blood supply from branches of the PV and to a much lesser extent from the HA. In contrast, the blood supply of hepatic metastases is reported to rely almost entirely on the HA (Strohmeyer, 1986). Consequently, most regional approaches have been made using the HA. More recently, however, attention has been drawn to the PV as very small liver tumours (< 5 mm), as well as the outer rim of larger hepatic metastases, are fed mainly by portal branches (Archer, 1989). In addition, most colorectal tumours are drained via the PV, suggesting that spreading tumour cells will first proliferate in the portal system. Thus, by using the HA as well as the PV, drugs will reach both established and newly formed (micro) metastases. Taking this into consideration, we performed IHP via both the HA as well as the PV. However, as most normal hepatic parenchyma tissue is supplied primarily by the PV, it could be speculated that infusion via the PV might induce significant hepatotoxicity. Indeed, Boddie et al (1979) performed IHP solely via the PV and demonstrated significant hepatic damage. In accordance with most other reports on IHP, we have not been able to confirm these findings (Skibba, 1983, 1988; Sindelar, 1985; Van de Velde, 1986; Aigner, 1988; Hafstrom, 1994).

At present, it is unknown which drug, or combination of drugs, would provide antitumoral efficacy in the IHP setting. TNF-α with and without melphalan was selected for this study based on its clinical success (100% limb salvage and a 90% overall response) in isolated limb perfusions for irresectable melanoma and sarcoma (Eggermont, 1994; Liénard, 1994). As at least part of the antitumour effect of TNF-α relies on the destruction of the tumour-associated vessels, irrespective of tumour histology (Watanabe,
1988; Renard, 1994; Cid, 1994), we reasoned that this combination might well be effective against colorectal hepatic metastases. Indeed, Van der Schelling et al (1992) have recently shown that intratumoral administration of rHTNF-α, under ultrasonographic guidance, was able to stabilize disease in eight patients with hepatic metastases at the cost of minimal systemic symptoms. As demonstrated by Mavligit et al (1992), HA infusion of rHTNF-α permits a more than six-fold dose increase of the maximum tolerated systemic (i.v.) dose before adverse systemic side-effects are noted. In this setting, TNF-α was found to induce tumour regression in approximately 30% of patients with irresectable colorectal liver metastases (Mavligit, 1992). Because of the synergy between melphalan and TNF-α, as demonstrated in earlier reports (Eggermont, 1996a,b; Liénard, 1994), melphalan was chosen over 5-FU, the drug most frequently used in conventional regimes against colorectal (liver) metastases. For reasons of comprehensiveness, we also performed IHP with TNF-α and 5-FU in two pigs. No mortality was encountered, and (hepatic) response patterns were identical to the ones described above (data not shown).

On the other hand, Kahky et al (1990) have shown that intraportal administration of 100 µg kg−1 day−1 rHTNF-α results in 100% mortality in rats. Histological examination in their study revealed mild passive congestion of the liver combined with severe pulmonary oedema. As systemic administration of the same dose of rHTNF-α did not result in any death, it is unlikely that the high mortality after intraportal injection was caused solely by TNF-α (Kahky, 1990). TNF-α has been demonstrated to induce the production of various cytokines (including IL-1, IL-6 and TNF-α) by macrophages (i.e. Kupffer cells) (Shirahama, 1988; Busam, 1990). As the vast majority of hepatic Kupffer cells are situated in the (peri) portal area, such a secondary cytokine release might explain the observed mortality. As far as we can judge, IHP with rHTNF-α and melphalan in the healthy pig does not lead to such dramatic cytokine-related side-effects.

In conclusion, hyperthermic IHP with rHTNF-α and melphalan in pigs is technically feasible, resulting in minimal systemic leakage of drugs and mild, transient hepatotoxicity. The addition of rHTNF-α and melphalan in the perfusate does not lead to additional hepatotoxic side-effects. As pig liver physiology is similar to humans, IHP with rHTNF-α and melphalan should be considered for phase I evaluation in patients with irresectable hepatic malignancy.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge Janne de Kam, Enno Collij, Henk Donck and Rob Meijer for their excellent technical assistance during the operative procedures. They are also indebted to the Department of Extracorporeal Circulation of the University Hospital Rotterdam (Head: Mrs M Wijers) for their superb perfusionists’ skills and cooperation.

REFERENCES


Cil MC, Kleinman HK, Grant DS, Schnaper HW, Forre AS and Hoffman GS (1994) Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. J Clin Invest 93: 17–25


© Cancer Research Campaign 1997
Isolated hepatic perfusion with TNF-α


© Cancer Research Campaign 1997

British Journal of Cancer (1997) 75(10), 1447–1453